JP2025501410A - 重水素化有機化合物およびその使用 - Google Patents

重水素化有機化合物およびその使用 Download PDF

Info

Publication number
JP2025501410A
JP2025501410A JP2024561730A JP2024561730A JP2025501410A JP 2025501410 A JP2025501410 A JP 2025501410A JP 2024561730 A JP2024561730 A JP 2024561730A JP 2024561730 A JP2024561730 A JP 2024561730A JP 2025501410 A JP2025501410 A JP 2025501410A
Authority
JP
Japan
Prior art keywords
compound
disorder
formula
pharma
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024561730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501410A5 (https=
Inventor
バドダリア，クリシュナ
バノーバー，キンバリー
セラッツ，ジョルディ
スダルサン，ビクラム
ガービー，デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Engrail Therapeutics Inc
Original Assignee
Engrail Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engrail Therapeutics Inc filed Critical Engrail Therapeutics Inc
Publication of JP2025501410A publication Critical patent/JP2025501410A/ja
Publication of JP2025501410A5 publication Critical patent/JP2025501410A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024561730A 2022-01-03 2023-01-03 重水素化有機化合物およびその使用 Pending JP2025501410A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263296134P 2022-01-03 2022-01-03
US63/296,134 2022-01-03
US202263345007P 2022-05-23 2022-05-23
US63/345,007 2022-05-23
US202263384992P 2022-11-25 2022-11-25
US63/384,992 2022-11-25
PCT/US2023/010050 WO2023130117A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2025501410A true JP2025501410A (ja) 2025-01-17
JP2025501410A5 JP2025501410A5 (https=) 2026-01-15

Family

ID=87000368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024561730A Pending JP2025501410A (ja) 2022-01-03 2023-01-03 重水素化有機化合物およびその使用

Country Status (10)

Country Link
US (1) US20250091990A1 (https=)
EP (1) EP4460490A4 (https=)
JP (1) JP2025501410A (https=)
KR (1) KR20240132476A (https=)
AU (1) AU2023204432A1 (https=)
CA (1) CA3242751A1 (https=)
IL (1) IL314019A (https=)
MX (1) MX2024008372A (https=)
TW (1) TW202340145A (https=)
WO (1) WO2023130117A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202333671A (zh) 2022-01-03 2023-09-01 美商恩格瑞爾療法公司 氘化有機化合物及其用途
TW202517609A (zh) 2023-07-02 2025-05-01 美商英格瑞治療公司 氘化有機化合物及其用途(二)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102373288B1 (ko) * 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CN104744333A (zh) * 2013-12-26 2015-07-01 张云 一种奈莫必利的生产方法

Also Published As

Publication number Publication date
WO2023130117A1 (en) 2023-07-06
TW202340145A (zh) 2023-10-16
US20250091990A1 (en) 2025-03-20
EP4460490A1 (en) 2024-11-13
AU2023204432A1 (en) 2024-07-18
EP4460490A4 (en) 2026-03-18
CA3242751A1 (en) 2023-07-06
IL314019A (en) 2024-08-01
KR20240132476A (ko) 2024-09-03
MX2024008372A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
US20110312961A1 (en) 2,5-Disubstituted Morpholine Orexin REceptor Antagonists
US20190083420A1 (en) Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
CN115884971A (zh) 取代的哌啶化合物及其用途
US8901151B2 (en) Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide
JP6975515B2 (ja) Ｔｒｐａ１モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物
US12606523B2 (en) Deuterated organic compounds and uses thereof
RS52743B (sr) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciklo[2.2.2]okt-3-il)benzofuran-2-karboksamid, novi oblici soli i postupci za njihovu upotrebu
CN114591352B (zh) 一种三唑并哒嗪类化合物及其应用
US20260098011A1 (en) Deuterated organic compounds and uses thereof
JP2025501410A (ja) 重水素化有機化合物およびその使用
TWI644914B (zh) １，２，４－三唑并［４，３－ａ］吡啶化合物及其作為ＭＧＬＵＲ２受體之正向異位調節劑的用途
JP2022036285A (ja) ピペリジニルノシセプチン受容体化合物
TW201245197A (en) Substituted [(5h-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists
CN118804910A (zh) 氘代有机化合物及其用途
CN118804746A (zh) 氘代有机化合物及其用途
WO2023156565A1 (en) Bridged ring compounds and their therapeutic use as cns agents
EA045865B1 (ru) Замещенные пиперидиновые соединения и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260416